NCT06678165

A Pilot Study on the Safety and Efficacy of YOLT-204 for Transfusion-Dependent Beta-Thalassemia

• Status: Not Yet Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 3 (estimated)
• Sponsor: First Affiliated Hospital of Guangxi Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 35 Years
• Healthy volunteers: Not accepted

Summary

This study is a single-arm, open-label, dose-escalation trial, planning to enroll 3-9 patients with transfusion-dependent β-thalassemia, aimed at assessing the safety and tolerability of a single-dose of YOLT-204 in patients with transfusion-dependent β-thalassemia; to preliminarily evaluate the impact of a single -dose of YOLT-204 on the levels of fetal hemoglobin in the plasma

Conditions

• Transfusion Dependent Beta Thalassemia

Interventions

Type	Name	Description
DRUG	YOLT-204	The intervention group will receive YOLT-204 on day0

Timeline

• Start date: 2024-12-31
• Primary completion: 2026-06-01
• Completion: 2026-06-01
• First posted: 2024-11-07
• Last updated: 2024-11-07

Locations

1 site across 1 country: China